CN1150900C - 含活性物质和环糊精的口服药物组合物 - Google Patents

含活性物质和环糊精的口服药物组合物 Download PDF

Info

Publication number
CN1150900C
CN1150900C CNB988067641A CN98806764A CN1150900C CN 1150900 C CN1150900 C CN 1150900C CN B988067641 A CNB988067641 A CN B988067641A CN 98806764 A CN98806764 A CN 98806764A CN 1150900 C CN1150900 C CN 1150900C
Authority
CN
China
Prior art keywords
cyclodextrin
pharmaceutical composition
active substance
cetirizine
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB988067641A
Other languages
English (en)
Chinese (zh)
Other versions
CN1261799A (zh
Inventor
D
D·法纳拉
M·伯维尔
P·诺尔福
H·弗兰克斯
M·德利尔斯
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3890611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1150900(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB SA filed Critical UCB SA
Publication of CN1261799A publication Critical patent/CN1261799A/zh
Application granted granted Critical
Publication of CN1150900C publication Critical patent/CN1150900C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB988067641A 1997-07-03 1998-07-02 含活性物质和环糊精的口服药物组合物 Expired - Lifetime CN1150900C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE9700572A BE1011251A3 (fr) 1997-07-03 1997-07-03 Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
BE9700572 1997-07-03

Publications (2)

Publication Number Publication Date
CN1261799A CN1261799A (zh) 2000-08-02
CN1150900C true CN1150900C (zh) 2004-05-26

Family

ID=3890611

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988067641A Expired - Lifetime CN1150900C (zh) 1997-07-03 1998-07-02 含活性物质和环糊精的口服药物组合物

Country Status (20)

Country Link
US (1) US6455533B1 (enExample)
EP (1) EP0994710B2 (enExample)
JP (2) JP2002508773A (enExample)
KR (1) KR100551510B1 (enExample)
CN (1) CN1150900C (enExample)
AT (1) ATE224717T1 (enExample)
AU (1) AU727140B2 (enExample)
BE (1) BE1011251A3 (enExample)
BR (1) BR9810495A (enExample)
CA (1) CA2294783C (enExample)
DE (1) DE69808297T3 (enExample)
DK (1) DK0994710T4 (enExample)
ES (1) ES2184293T5 (enExample)
ID (1) ID23806A (enExample)
IL (1) IL133397A (enExample)
NZ (1) NZ501820A (enExample)
PL (1) PL192348B1 (enExample)
PT (1) PT994710E (enExample)
RU (1) RU2192863C2 (enExample)
WO (1) WO1999001133A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
US20040213839A1 (en) * 2001-02-05 2004-10-28 Andrew Favara Methods and compositions for reducing the taste of pharmaceutically active agents
NZ534039A (en) * 2002-01-15 2006-08-31 Ucb Farchim S Formulations of pharmaceutical compositions for oral administration
PL372904A1 (en) * 2002-04-04 2005-08-08 Pfizer Products Inc. Palatable chewable tablet
CA2574602A1 (en) * 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
US20060198885A1 (en) * 2005-02-22 2006-09-07 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical composition
US20070086974A1 (en) * 2005-10-06 2007-04-19 Gawande Rahul S Cetirizine compositions
US20090269393A1 (en) * 2006-06-12 2009-10-29 Jubliant Organosys Limited Chewable Bilayer Tablet Formulation
JP2008143807A (ja) * 2006-12-07 2008-06-26 Sato Pharmaceutical Co Ltd 感冒薬カプセル剤及びその製造方法
EP2550967A1 (en) * 2007-07-11 2013-01-30 Fertin Pharma A/S Compressed chewing gum tablet comprising taste-masking agent
US20100260818A1 (en) * 2007-07-11 2010-10-14 Fertin Pharma A/S Stable medicated chewing gum comprising cyclodextrin inclusion complex
WO2009054432A1 (ja) * 2007-10-26 2009-04-30 Daiichi Sankyo Company, Limited 口腔内速崩壊性医薬組成物およびその製造方法
US8138192B2 (en) * 2007-10-31 2012-03-20 Genebiology, Inc. Injectable meclizine formulations and methods
WO2009061465A1 (en) * 2007-11-06 2009-05-14 Teva Pharmaceutical Industries Ltd. Chewable formulations
ES2564056T3 (es) * 2008-09-05 2016-03-17 Johnson & Johnson Consumer Inc. Método para hacer pastillas de cetirizina
WO2011110939A2 (en) 2010-03-11 2011-09-15 Rubicon Research Private Limited Pharmaceutical compositions of substituted benzhydrylpiperazines
WO2011150859A1 (en) * 2010-06-04 2011-12-08 Comprehensive Drug Enterprises Ltd Oral meclizine aqueous formulations with taste flavoring agent
CN101905027A (zh) * 2010-07-27 2010-12-08 北京华禧联合科技发展有限公司 含米格列奈钙和环糊精的口服药用组合物
AU2011302293B2 (en) 2010-09-13 2015-11-26 Bev-Rx, Inc. Aqueous drug delivery system comprising off - flavor masking agent
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
RU2589833C2 (ru) * 2013-12-12 2016-07-10 Общество С Ограниченной Ответственностью "Фарма Старт" Твердая лекарственная форма препарата седативного и снотворного действия
DK3122330T3 (en) * 2014-03-27 2018-10-22 Ucb Farchim Sa Pharmaceutical compositions comprising levocetirizine
IL302218B2 (en) 2014-08-28 2024-10-01 Eisai R&D Man Co Ltd Methods for manufacturing high-purity lenvatinib and its derivatives
JP6792546B2 (ja) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
EP3311841B1 (en) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Anticancer agent
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
RU2750539C2 (ru) 2017-02-08 2021-06-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция для лечения опухоли
AU2018269996A1 (en) 2017-05-16 2019-11-21 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
KR102110304B1 (ko) * 2017-06-30 2020-05-14 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성 및 복약순응도가 향상된 복합 츄어블정 및 그 제조방법
EP4099977A1 (en) * 2020-02-03 2022-12-14 Johnson & Johnson Consumer Inc. A single layer chewable tablet comprising cetirizine
WO2022106923A1 (en) 2020-11-18 2022-05-27 BioPharma Synergies, S. L. Orodispersible powder composition comprising an antihistamine compound

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK154078C (da) * 1981-02-06 1989-05-22 Ucb Sa Analogifremgangsmaade til fremstilling af 2-(2-(4-(diphenyl-methyl)-1-piperazinyl)ethoxy)-acetamider eller syreadditionssalte heraf
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
JPS60204712A (ja) * 1984-03-29 1985-10-16 Ss Pharmaceut Co Ltd 塩酸メクリジンの安定化液状組成物
JPS63243031A (ja) † 1987-03-28 1988-10-07 Tokyo Tanabe Co Ltd 胆汁酸の固形製剤
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
CA2145410A1 (en) † 1992-09-24 1994-03-31 Nancy M. Gray Compositions for treating allergic disorders using (-) cetirizine
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
ES2166811T3 (es) * 1993-12-01 2002-05-01 Byk Gulden Lomberg Chem Fab Amino-alquil-amino-piridinas sustituidas.
US5866179A (en) 1996-05-03 1999-02-02 Avant-Garde Technologies & Products S.A. Medicated chewing gum and a process for preparation thereof
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
CA2574602A1 (en) * 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form

Also Published As

Publication number Publication date
DE69808297D1 (de) 2002-10-31
AU727140B2 (en) 2000-12-07
KR100551510B1 (ko) 2006-02-13
PT994710E (pt) 2003-02-28
NZ501820A (en) 2000-10-27
CA2294783A1 (fr) 1999-01-14
EP0994710A1 (fr) 2000-04-26
US20020032217A1 (en) 2002-03-14
JP2002508773A (ja) 2002-03-19
ES2184293T5 (es) 2006-01-16
DK0994710T4 (da) 2005-10-17
JP2007091760A (ja) 2007-04-12
PL337794A1 (en) 2000-09-11
ID23806A (id) 2000-05-11
DE69808297T3 (de) 2006-01-19
AU8201598A (en) 1999-01-25
US6455533B1 (en) 2002-09-24
CN1261799A (zh) 2000-08-02
KR20010014398A (ko) 2001-02-26
DK0994710T3 (da) 2003-01-20
EP0994710B1 (fr) 2002-09-25
IL133397A0 (en) 2001-04-30
PL192348B1 (pl) 2006-10-31
BE1011251A3 (fr) 1999-06-01
BR9810495A (pt) 2000-09-12
WO1999001133A1 (fr) 1999-01-14
ES2184293T3 (es) 2003-04-01
IL133397A (en) 2005-07-25
CA2294783C (fr) 2006-11-14
RU2192863C2 (ru) 2002-11-20
EP0994710B2 (fr) 2005-09-21
ATE224717T1 (de) 2002-10-15
DE69808297T2 (de) 2003-04-17
HK1029060A1 (en) 2001-03-23

Similar Documents

Publication Publication Date Title
CN1150900C (zh) 含活性物质和环糊精的口服药物组合物
CN1074922C (zh) 含有帕罗西汀树脂酸盐的口服液体组合物
TW473392B (en) Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
JP3877787B2 (ja) 薬学組成物
JP2002503267A (ja) スルホアルキルエーテルシクロデキストリンと治療剤との物理的混合物を含有する固形製剤
AU2002302147B2 (en) Pharmaceutical composition
HU225236B1 (en) Pharmaceutical formulations containing darifenacin
JPWO2008032726A1 (ja) 光に対して安定なラモセトロンの固形医薬組成物
US6077871A (en) Droloxifene pharmaceutical compositions
CN101160115A (zh) 一种包含诺美婷自由基盐的固体分散物及其制备方法
EP1680398A1 (en) Thiourea derivative-containing pharmaceutical composition having improved solubility and bioavailability
EP1452169A1 (en) Aqueous base liquid pharmaceutical compositions in suspension form for the oral administration of ibuprofen
CN1198654C (zh) 药用复合物
HK1029060B (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
WO1989006959A1 (fr) Preparation pharmaceutique a liberation amelioree
US20250064798A1 (en) Vilazodone composition, pharmaceutical preparation thereof, preparation therefor, and use thereof
CN1798562A (zh) 用于口服给药的包含伊曲康唑的组合物
CN116650487B (zh) 一种氢溴酸伏硫西汀药物组合物及其制备方法和其应用
MXPA99011899A (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
CN100435847C (zh) 含有难溶解性主药之持续释放配方
MXPA98009888A (en) Pharmaceutical compositions of droloxif
HK1044713A (en) Pharmaceutical complex

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20090123

Address after: Swiss Bielefeld

Patentee after: UCB Farchim S. A.

Address before: Brussels, Belgium

Patentee before: UCB, S.A.

ASS Succession or assignment of patent right

Owner name: UCB FARM CO., LTD.

Free format text: FORMER OWNER: UCB CO.

Effective date: 20090123

CX01 Expiry of patent term

Granted publication date: 20040526

CX01 Expiry of patent term